NCT02682407Phase 2Terminated

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

Study sponsor: Omeros Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-08-25Actual
Enrollment · participants31Actual
Source updated2026-03-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy subjects with treatment related adverse events (AE). Measure: Cohort 4: Proportion of IgAN patients of Asian descent with treatment related AEs. Measure: Cohort 4: Change from baseline in serum and urine complement component levels.. After: Measure: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE). Measure: Cohort 4: Proportion of IgAN Participants of Asian Descent With Treatment Related AEs. Measure: Cohort 4: Change From Baseline in Serum and Urine Complement Component Levels..

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 54 participants (planned). After: 31 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2020. After: 25 Aug 2020.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source